Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Dec 10, 2023 11:41pm
204 Views
Post# 35777286

RE:RE:Adstiladrin data shown at end of Nov at big UroOncology meet

RE:RE:Adstiladrin data shown at end of Nov at big UroOncology meet
The more I think of it this is the worst data for adstiladrin. I really shows that you do all these expensive bladder instillations (6 induction plus 12 per year for total of 30 in 3 years) and no patient really gets to feel like they are in the clear. By 3 years there is only a 1/8ish chance of being CR still.

In a way it is lucky to have this data BEFORE BTD submission as now TLT can really sell the application with that reference material. I'm really hoping that the 18 month data ( which already exists out there as all 14 CR's to date are past 18m) will show that the 14 CRs at 450 are still CR at 540. If so then it would be the only agent that has a sustained CR after you are done the protocol. If you look at all patiets that are green CR 3 in a row, only 11% fall off (i.e. 270-365) and 100% of the 4 in a row CR's stay that way to 450. At 450 they would have been 9 m out from last intervention. Cool.


<< Previous
Bullboard Posts
Next >>